We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bone marrow cells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-making
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program / Ladetto, M; Lobetti Bodoni, C; Mantoan, B; Ceccarelli, M; Boccomini, C; Genuardi, E; Chiappella, A; Baldini, L; Rossi, G; Pulsoni, Alessandro; Di Raimondo, F; Rigacci, L; Pinto, A; Galimberti, S; Bari, A; Rota Scalabrini, D; Ferrari, A; Zaja, F; Gallamini, A; Specchia, G; Musto, P; Rossi, Fg; Gamba, E; Evangelista, A; Vitolo, U; Lobetti Bodoni, C; Mantoan, B; Genuardi, E; Boccadoro, M; Ladetto, M; Ciccone, G; Evangelista, A; Ceccarelli, M; Boccomini, C; Chiappella, A; Botto, B; Orsucci, L; Vitolo, U; Goldaniga, M; Rossi, Fg; Baldini, L; Bottelli, C; Tucci, A; Rossi, G; Pulsoni, A; De Angelis, F; Russo, E; Martelli, M; Foa, Roberto; Di Raimondo, F; Chiarenza, A; Rigacci, L; Puccini, B; Bosi, A; Pinto, A; Petrini, M; Galimberti, S; Bari, A; Sacchi, S; Federico, M; Rota Scalabrini, D; Aglietta, M; Ferrari, A; Alvarez De Celis, I; Merli, F; Zaja, F; Fanin, R; Castellino, C; Gallamini, A; Parvis, G; Saglio, G; Perrone, T; Specchia, G; Musto, P; Gamba, E; Corradini, P; Pogliani, Em; Liberati, Am; Leone, G; Patti, C; Fioritoni, G; Rusconi, C; Morra, E; Tonso, A; Cabras, G; Angelucci, E; Rossi, A; Rambaldi, A; Cortelazzo, S; Morandi, S; Lanza, F; Pizzolo, G; Amadori, S; Zinzani, Pl; Stelitano, C; Nobile, F.. - In: BLOOD. - ISSN 0006-4971. - 23:122(2013), pp. 3759-3766. [10.1182/blood-2013-06-507319]
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
PULSONI, Alessandro;FOA, Roberto;
2013
Abstract
We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bone marrow cells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-makingI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
